| ISIN | LU2041626032 | 
|---|---|
| Valor Number | 49473298 | 
| Bloomberg Global ID | |
| Fund Name | JSS Sustainable Equity - Future Health C CHF acc | 
| Fund Provider | 
                                            
                                            
                                            J. Safra Sarasin Investmentfonds AG
                                            
    
        Basel, Switzerland Phone: +41 58 317 44 44 Web: www.jsafrasarasin.com  | 
                                    
| Fund Provider | J. Safra Sarasin Investmentfonds AG | 
| Representative in Switzerland | 
                                            J. Safra Sarasin Investmentfonds AG Basel Phone: +41 58 317 44 00  | 
                                    
| Distributor(s) | 
                                            
                                                Bank J. Safra Sarasin AG Basel Phone: +41 58 317 44 00  | 
                                    
| Asset Class | Equities | 
| EFC Category | |
| Distribution Policy | Accumulation | 
| Home Country | Luxembourg | 
| Issuing Condition | The fund management company and/or distributor charges an issuing commission (different commissions can be charged for the same fund depending on the sales channel) | 
| Redemption Condition | The fund does not charge any redemption commission and/or fees (units are redeemed at the NAV) | 
| Investment Strategy *** | The investment objective of the fund is to achieve long-term capital growth. The Reference Currency of the Sub-Fund is the US Dollar (USD). The assets of the fund are mainly invested worldwide either directly (min. 67% of the SubFund’s assets) or indirectly in equity securities that offer an exposure to one or multiple emerging and transformational health trends. The Sub-Fund invests in leading companies and niche players whose products and services contribute to the improvement of health outcome and the dampening of rising healthcare costs. | 
| Peculiarities | 
| Current Price * | 97.90 CHF | 31.10.2025 | 
|---|---|---|
| Previous Price * | 98.02 CHF | 30.10.2025 | 
| 52 Week High * | 105.30 CHF | 30.01.2025 | 
| 52 Week Low * | 85.52 CHF | 11.04.2025 | 
| NAV * | 97.90 CHF | 31.10.2025 | 
| Issue Price * | ||
| Redemption Price * | ||
| Closing Price * | ||
| Indicative Minimum Price | ||
| Fund Assets *** | 107,709,287 | |
| Unit/Share Assets *** | 9,908,126 | |
| Trading Information SIX | ||
| YTD Performance | -0.89% | 
        31.12.2024 - 31.10.2025
        31.12.2024 31.10.2025  | 
                                    
|---|---|---|
| 1 month | +6.18% | 
        30.09.2025 - 31.10.2025
        30.09.2025 31.10.2025  | 
                                    
| 3 months | +11.17% | 
        31.07.2025 - 31.10.2025
        31.07.2025 31.10.2025  | 
                                    
| 6 months | +5.02% | 
        30.04.2025 - 31.10.2025
        30.04.2025 31.10.2025  | 
                                    
| 1 year | -1.65% | 
        31.10.2024 - 31.10.2025
        31.10.2024 31.10.2025  | 
                                    
| 2 years | +13.92% | 
        31.10.2023 - 31.10.2025
        31.10.2023 31.10.2025  | 
                                    
| 3 years | -13.52% | 
        31.10.2022 - 31.10.2025
        31.10.2022 31.10.2025  | 
                                    
| 5 years | -7.99% | 
        02.11.2020 - 31.10.2025
        02.11.2020 31.10.2025  | 
                                    
| Equity Participation Rate in % | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Share of Total Fund Assets in % | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Real Estate Rate in % | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ADDI | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ADDI Date | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Johnson & Johnson | 8.00% | |
|---|---|---|
| Eli Lilly and Co | 7.24% | |
| Danaher Corp | 6.45% | |
| Sanofi SA | 6.21% | |
| argenx SE | 5.71% | |
| Boston Scientific Corp | 4.87% | |
| AbbVie Inc | 4.65% | |
| Fresenius SE & Co KGaA | 4.63% | |
| Merck & Co Inc | 4.63% | |
| Lonza Group Ltd | 4.45% | |
| Last data update | 30.09.2025 | |
| TER | 1.38% | 
|---|---|
| TER date | 30.04.2025 | 
| Performance Fee *** | |
| PTR | |
| Max. Management Fee *** | 1.50% | 
| Ongoing Charges *** | 1.38% | 
| 
                                            SRRI ***
                                             | 
                                    |
| SRRI date *** | 30.09.2025 |